

Supplementary Table 7. The risks of any cancer and organ-specific cancers in original population before and after PSM according to the status of NDMA

PSM	Cancer	Any cancer			Bladder cancer			Breast cancer ^{a)}			
		Event	aHR (95% CI)	<i>p</i> value	Event	aHR (95% CI)	<i>p</i> value	Event	aHR (95% CI)	<i>p</i> value	
Before PSM ^{b)}	Overall	NDMA-unexposed	410,341	1.000	-	17,768	1.000	-	14,354	1.000	-
		Eventually NDMA-unexposed	27,566	0.975 (0.963–0.988)	< 0.001*	1,146	0.868 (0.817–0.924)	< 0.001*	885	0.985 (0.918–1.056)	0.667
		NDMA-exposed	46,234	0.984 (0.974–0.993)	0.001	2,021	0.921 (0.879–0.966)	0.001*	1,455	0.910 (0.861–0.963)	0.001*
	6 mon exc.	NDMA-unexposed	225,149	1.000	-	10,293	1.000	-	7,626	1.000	-
		Eventually NDMA-unexposed	25,709	1.348 (1.330–1.366)	< 0.001*	1,082	1.206 (1.130–1.287)	< 0.001*	831	1.428 (1.325–1.538)	< 0.001*
		NDMA-exposed	43,789	1.277 (1.264–1.291)	< 0.001*	1,915	1.181 (1.123–1.242)	< 0.001*	1,378	1.211 (1.141–1.284)	< 0.001*
	1-year exc.	NDMA-unexposed	22,439	1.000	-	9,399	1.000	-	6,867	1.000	-
		Eventually NDMA-unexposed	2,606	1.241 (1.223–1.259)	< 0.001*	924	1.105 (1.030–1.185)	0.005	727	1.334 (1.232–1.444)	< 0.001*
		NDMA-exposed	4,558	1.206 (1.193–1.220)	< 0.001*	1,722	1.127 (1.069–1.188)	< 0.001*	1,234	1.152 (1.082–1.226)	< 0.001*
	2-year exc. ^{d)}	NDMA-unexposed	17,421	1.000	-	7,564	1.000	-	5,416	1.000	-
		Eventually NDMA-unexposed	1,860	1.097 (1.079–1.116)	< 0.001*	691	1.008 (0.930–1.093)	0.850	513	1.173 (1.068–1.289)	0.001*
		NDMA-exposed	3,430	1.098 (1.084–1.113)	< 0.001*	1,320	1.036 (0.975–1.100)	0.255	880	1.005 (0.934–1.081)	0.896
1:1 PSM ^{c)}	Overall	NDMA-unexposed	34,300	1.000	-	1,477	1.000	-	1,094	1.000	-
		NDMA-exposed	16,250	1.025 (1.004–1.047)	0.018	708	0.961 (0.871–1.061)	0.433	499	0.964 (0.858–1.084)	0.541
	6 mon exc.	NDMA-unexposed	14,086	1.000	-	659	1.000	-	510	1.000	-
		NDMA-exposed	14,313	1.343 (1.311–1.376)	< 0.001*	671	1.261 (1.128–1.409)	< 0.001*	472	1.211 (1.063–1.379)	0.004
	1-year exc.	NDMA-unexposed	12,311	1.000	-	604	1.000	-	458	1.000	-
		NDMA-exposed	12,620	1.261 (1.229–1.293)	< 0.001*	610	1.188 (1.059–1.333)	0.003*	429	1.145 (1.000–1.311)	0.051
	2-year exc. ^{d)}	NDMA-unexposed	9,206	1.000	-	473	1.000	-	346	1.000	-
		NDMA-exposed	9,364	1.146 (1.113–1.180)	< 0.001*	476	1.097 (0.964–1.248)	0.159	309	0.974 (0.833–1.138)	0.737
1:1:1 PSM ^{c)}	Overall	NDMA-unexposed	33,635	1.000	-	1,410	1.000	-	1,032	1.000	-
		Eventually NDMA-unexposed	9,266	1.032 (1.006–1.058)	0.017	421	1.049 (0.929–1.183)	0.440	283	1.005 (0.868–1.163)	0.946
		NDMA-exposed	11,481	1.040 (1.016–1.066)	0.001	501	1.027 (0.915–1.152)	0.653	333	0.965 (0.838–1.110)	0.613

Supplementary Table 7. Continued

	6 mon exc. NDMA-unexposed	9,006	1.000	-	446	1.000	-	326	1.000	-
	Eventually NDMA-unexposed	7,518	1.548 (1.499–1.598)	< 0.001*	391	1.578 (1.370–1.817)	< 0.001*	267	1.511 (1.276–1.789)	< 0.001*
	NDMA-exposed	9,251	1.520 (1.475–1.567)	< 0.001*	472	1.503 (1.312–1.722)	< 0.001*	310	1.368 (1.162–1.612)	< 0.001*
	1-year exc. NDMA-unexposed	7,702	1.000	-	407	1.000	-	289	1.000	-
	Eventually NDMA-unexposed	6,308	1.365 (1.319–1.412)	< 0.001*	325	1.303 (1.122–1.514)	< 0.001*	231	1.332 (1.114–1.592)	0.002*
	NDMA-exposed	8,022	1.371 (1.327–1.416)	< 0.001*	427	1.337 (1.162–1.538)	< 0.001*	275	1.217 (1.025–1.444)	0.025
2-year exc. ^{d)}	NDMA-unexposed	5,568	1.000	-	311	1.000	-	214	1.000	-
	Eventually NDMA-unexposed	4,317	1.138 (1.093–1.184)	< 0.001*	253	1.188 (1.004–1.406)	0.044	173	1.170 (0.955–1.434)	0.130
	NDMA-exposed	5,689	1.172 (1.129–1.217)	< 0.001*	329	1.197 (1.023–1.402)	0.025	196	1.009 (0.829–1.229)	0.928
PSM	Cancer	Colorectal cancer			Gallbladder and etc. cancer			Kidney cancer		
		Event	aHR (95% CI)	p value	Event	aHR (95% CI)	p value	Event	aHR (95% CI)	p value
Before PSM ^{b)} Overall	NDMA-unexposed	47,800	1.000	-	9,725	1.000	-	9,322	1.000	-
	Eventually NDMA-unexposed	3,233	1.048 (1.010–1.087)	0.013	770	1.051 (0.974–1.134)	0.201	595	0.915 (0.840–0.997)	0.043
	NDMA-exposed	5,437	1.032 (1.003–1.063)	0.032	1,304	1.024 (0.964–1.087)	0.447	993	0.930 (0.869–0.995)	0.036
6 mon exc.	NDMA-unexposed	25,211	1.000	-	6,129	1.000	-	5,123	1.000	-
	Eventually NDMA-unexposed	3,014	1.504 (1.446–1.565)	< 0.001*	719	1.365 (1.260–1.480)	< 0.001*	551	1.291 (1.179–1.415)	< 0.001*
	NDMA-exposed	5,121	1.375 (1.333–1.418)	< 0.001*	1,224	1.247 (1.171–1.329)	< 0.001*	937	1.236 (1.150–1.328)	< 0.001*
1-year exc.	NDMA-unexposed	22,439	1.000	-	5,492	1.000	-	4,629	1.000	-
	Eventually NDMA-unexposed	2,606	1.374 (1.318–1.434)	< 0.001*	615	1.259 (1.154–1.373)	< 0.001*	480	1.198 (1.087–1.321)	< 0.001*
	NDMA-exposed	4,558	1.295 (1.253–1.339)	< 0.001*	1,104	1.203 (1.126–1.286)	< 0.001*	833	1.165 (1.080–1.257)	< 0.001*
2-year exc. ^{d)}	NDMA-unexposed	17,421	1.000	-	4,384	1.000	-	3,698	1.000	-
	Eventually NDMA-unexposed	1,860	1.203 (1.144–1.264)	< 0.001*	438	1.092 (0.986–1.209)	0.091	368	1.138 (1.018–1.272)	0.023
	NDMA-exposed	3,430	1.184 (1.140–1.230)	< 0.001*	829	1.079 (1.000–1.165)	0.050	644	1.099 (1.008–1.198)	0.032
1:1 PSM ^{c)} Overall	NDMA-unexposed	3,920	1.000	-	762	1.000	-	720	1.000	-
	NDMA-exposed	1,764	1.043 (0.979–1.110)	0.191	402	0.987 (0.865–1.125)	0.840	343	0.992 (0.861–1.144)	0.916

Supplementary Table 7. Continued

	6 mon exc. NDMA-unexposed	1,568	1.000	-	412	1.000	-	319	1.000	-
	NDMA-exposed	1,647	1.403 (1.306–1.508)	< 0.001*	380	1.183 (1.025–1.366)	0.022	326	1.336 (1.138–1.568)	< 0.001*
	1-year exc. NDMA-unexposed	1,399	1.000	-	368	1.000	-	284	1.000	-
	NDMA-exposed	1,474	1.305 (1.211–1.407)	< 0.001*	349	1.155 (0.994–1.342)	0.060	282	1.199 (1.013–1.419)	0.035
	2-year exc. ^{d)} NDMA-unexposed	1,069	1.000	-	290	1.000	-	216	1.000	-
	NDMA-exposed	1,117	1.182 (1.086–1.287)	< 0.001*	261	1.007 (0.850–1.192)	0.938	231	1.208 (1.001–1.458)	0.049
1:1:1 PSM ^{d)} Overall	NDMA-unexposed	3,920	1.000	-	692	1.000	-	744	1.000	-
	Eventually NDMA-unexposed	1,000	1.049 (0.970–1.133)	0.229	248	1.062 (0.906–1.244)	0.459	200	0.953 (0.803–1.133)	0.587
	NDMA-exposed	1,236	1.051 (0.977–1.131)	0.178	273	0.951 (0.815–1.111)	0.530	251	0.973 (0.828–1.143)	0.740
	6 mon exc. NDMA-unexposed	1,077	1.000	-	296	1.000	-	223	1.000	-
	Eventually NDMA-unexposed	927	1.629 (1.486–1.785)	< 0.001*	229	1.393 (1.165–1.666)	< 0.001*	186	1.518 (1.240–1.858)	< 0.001*
	NDMA-exposed	1,130	1.561 (1.430–1.704)	< 0.001*	255	1.224 (1.028–1.458)	0.023	236	1.514 (1.250–1.835)	< 0.001*
	1-year exc. NDMA-unexposed	947	1.000	-	262	1.000	-	198	1.000	-
	Eventually NDMA-unexposed	795	1.420 (1.289–1.565)	< 0.001*	201	1.288 (1.066–1.555)	0.009	160	1.319 (1.066–1.633)	0.011
	NDMA-exposed	999	1.389 (1.267–1.522)	< 0.001*	237	1.183 (0.987–1.418)	0.069	203	1.304 (1.066–1.595)	0.010
	2-year exc. ^{d)} NDMA-unexposed	721	1.000	-	205	1.000	-	146	1.000	-
	Eventually NDMA-unexposed	578	1.198 (1.072–1.338)	0.001	140	1.013 (0.815–1.259)	0.911	129	1.319 (1.038–1.676)	0.024
	NDMA-exposed	751	1.203 (1.084–1.334)	< 0.001*	172	0.955 (0.777–1.172)	0.657	163	1.285 (1.025–1.612)	0.030
PSM	Cancer	Liver cancer			Lung cancer			Pancreatic cancer		
		Event	aHR (95% CI)	p value	Event	aHR (95% CI)	p value	Event	aHR (95% CI)	p value
Before PSM ^{b)} Overall	NDMA-unexposed	54,593	1.000	-	38,101	1.000	-	29,789	1.000	-
	Eventually NDMA-unexposed	3,703	1.027 (0.992–1.063)	0.135	2,824	1.002 (0.963–1.042)	0.933	2,137	0.959 (0.916–1.003)	0.068
	NDMA-exposed	5,638	0.954 (0.927–0.981)	0.001	4,718	0.979 (0.949–1.010)	0.191	3,630	0.973 (0.939–1.008)	0.132
	6 mon exc. NDMA-unexposed	28,856	1.000	-	22,900	1.000	-	17,804	1.000	-
	Eventually NDMA-unexposed	3,458	1.453 (1.400–1.507)	< 0.001*	2,643	1.360 (1.304–1.418)	< 0.001*	2,002	1.283 (1.223–1.346)	< 0.001*
	NDMA-exposed	5,299	1.259 (1.221–1.297)	< 0.001*	4,491	1.258 (1.217–1.300)	< 0.001*	3,444	1.224 (1.179–1.271)	< 0.001*

Supplementary Table 7. Continued

	1-year exc.	NDMA-unexposed	25,439	1.000	-	20,495	1.000	-	16,035	1.000	-
		Eventually NDMA-unexposed	2,947	1.321 (1.270–1.374)	< 0.001*	2,296	1.269 (1.213–1.327)	< 0.001*	1,769	1.215 (1.154–1.278)	< 0.001*
		NDMA-exposed	4,657	1.179 (1.141–1.217)	< 0.001*	3,970	1.187 (1.146–1.229)	< 0.001*	3,053	1.154 (1.109–1.201)	< 0.001*
	2-year exc. ^{d)}	NDMA-unexposed	19,512	1.000	-	16,122	1.000	-	12,923	1.000	-
		Eventually NDMA-unexposed	2,051	1.142 (1.089–1.197)	< 0.001*	2,991	1.135 (1.076–1.196)	< 0.001*	1,298	1.095 (1.032–1.162)	0.003*
		NDMA-exposed	3,406	1.058 (1.019–1.098)	0.003*	1,655	1.091 (1.048–1.136)	< 0.001*	2,331	1.061 (1.014–1.111)	0.010
1:1 PSM ^{c)}	Overall	NDMA-unexposed	4,541	1.000	-	2,989	1.000	-	2,518	1.000	-
		NDMA-exposed	1,951	0.988 (0.931–1.047)	0.677	1,595	1.041 (0.974–1.112)	0.236	1,347	1.062 (0.987–1.142)	0.105
	6 mon exc.	NDMA-unexposed	1,872	1.000	-	1,493	1.000	-	1,193	1.000	-
		NDMA-exposed	1,820	1.318 (1.233–1.410)	< 0.001*	1,515	1.348 (1.252–1.452)	< 0.001*	1,262	1.363 (1.255–1.479)	< 0.001*
	1-year exc.	NDMA-unexposed	1,638	1.000	-	1,321	1.000	-	1,052	1.000	-
		NDMA-exposed	1,596	1.209 (1.127–1.298)	< 0.001*	1,330	1.247 (1.153–1.348)	< 0.001*	1,111	1.252 (1.148–1.364)	< 0.001*
	2-year exc. ^{d)}	NDMA-unexposed	1,216	1.000	-	1,009	1.000	-	827	1.000	-
		NDMA-exposed	1,185	1.091 (1.006–1.183)	0.035	997	1.120 (1.025–1.224)	0.012	850	1.135 (1.030–1.250)	0.011
1:1:1 PSM ^{c)}	Overall	NDMA-unexposed	4,621	1.000	-	2,770	1.000	-	2,428	1.000	-
		Eventually NDMA-unexposed	1,230	1.097 (1.022–1.177)	0.010	879	1.022 (0.941–1.111)	0.606	724	1.011 (0.923–1.108)	0.813
		NDMA-exposed	1,390	1.004 (0.938–1.075)	0.914	1,104	1.043 (0.964–1.127)	0.295	971	1.102 (1.013–1.199)	0.023
	6 mon exc.	NDMA-unexposed	1,314	1.000	-	1,028	1.000	-	820	1.000	-
		Eventually NDMA-unexposed	1,125	1.685 (1.550–1.832)	< 0.001*	821	1.484 (1.349–1.632)	< 0.001*	667	1.507 (1.355–1.677)	< 0.001*
		NDMA-exposed	1,273	1.498 (1.381–1.625)	< 0.001*	1,037	1.479 (1.351–1.619)	< 0.001*	907	1.609 (1.457–1.777)	< 0.001*
	1-year exc.	NDMA-unexposed	1,125	1.000	-	899	1.000	-	714	1.000	-
		Eventually NDMA-unexposed	964	1.477 (1.352–1.614)	< 0.001*	711	1.333 (1.205–1.474)	< 0.001*	578	1.342 (1.199–1.501)	< 0.001*
		NDMA-exposed	1,111	1.326 (1.217–1.444)	< 0.001*	898	1.312 (1.193–1.444)	< 0.001*	790	1.424 (1.283–1.581)	< 0.001*
	2-year exc. ^{d)}	NDMA-unexposed	827	1.000	-	676	1.000	-	553	1.000	-
		Eventually NDMA-unexposed	666	1.192 (1.075–1.322)	< 0.001*	508	1.115 (0.993–1.253)	0.066	428	1.150 (1.012–1.307)	0.032
		NDMA-exposed	801	1.109 (1.005–1.224)	0.040	650	1.098 (0.985–1.225)	0.093	582	1.207 (1.072–1.358)	0.002*

Supplementary Table 7. Continued

PSM	Cancer	Prostate cancer ^{a)}			Stomach cancer			Thyroid cancer			
		Event	aHR (95% CI)	<i>p</i> value	Event	aHR (95% CI)	<i>p</i> value	Event	aHR (95% CI)	<i>p</i> value	
Before PSM ^{b)}	Overall	NDMA-unexposed	75,234	1.000	-	32,955	1.000	-	25,606	1.000	-
		Eventually NDMA-unexposed	4,934	0.948 (0.920–0.976)	< 0.001*	2,237	1.071 (1.024–1.119)	0.003*	1,439	0.918 (0.870–0.970)	0.002*
		NDMA-exposed	8,570	1.024 (1.000–1.048)	0.045	3,852	1.067 (1.031–1.104)	< 0.001*	2,387	0.917 (0.878–0.958)	< 0.001*
	6 mon exc.	NDMA-unexposed	41,112	1.000	-	17,975	1.000	-	11,950	1.000	-
		Eventually NDMA-unexposed	4,618	1.313 (1.272–1.356)	< 0.001*	2,067	1.478 (1.409–1.550)	< 0.001*	1,335	1.358 (1.281–1.440)	< 0.001*
		NDMA-exposed	8,149	1.342 (1.310–1.376)	< 0.001*	3,627	1.393 (1.343–1.445)	< 0.001*	2,237	1.262 (1.204–1.322)	< 0.001*
	1-year exc.	NDMA-unexposed	36,959	1.000	-	15,901	1.000	-	10,512	1.000	-
		Eventually NDMA-unexposed	3,965	1.204 (1.164–1.246)	< 0.001*	1,789	1.364 (1.297–1.436)	< 0.001*	1,152	1.235 (1.159–1.315)	< 0.001*
		NDMA-exposed	7,281	1.275 (1.243–1.308)	< 0.001*	3,191	1.312 (1.261–1.364)	< 0.001*	1,988	1.184 (1.127–1.244)	< 0.001*
	2-year exc. ^{d)}	NDMA-unexposed	29,353	1.000	-	12,218	1.000	-	8,247	1.000	-
		Eventually NDMA-unexposed	2,855	1.066 (1.024–1.109)	0.002*	1,235	1.168 (1.099–1.242)	< 0.001*	830	1.087 (1.009–1.170)	0.027
		NDMA-exposed	5,455	1.159 (1.125–1.194)	< 0.001*	2,337	1.182 (1.129–1.237)	< 0.001*	1,496	1.076 (1.017–1.149)	0.011
1:1 PSM ^{c)}	Overall	NDMA-unexposed	7,127	1.000	-	2,841	1.000	-	2,347	1.000	-
		NDMA-exposed	3,373	1.030 (0.985–1.078)	0.195	1,328	1.053 (0.980–1.132)	0.159	900	0.924 (0.847–1.007)	0.071
	6 mon exc.	NDMA-unexposed	2,991	1.000	-	1,216	1.000	-	855	1.000	-
		NDMA-exposed	3,111	1.352 (1.283–1.424)	< 0.001*	1,242	1.397 (1.287–1.516)	< 0.001*	847	1.285 (1.164–1.419)	< 0.001*
	1-year exc.	NDMA-unexposed	2,651	1.000	-	1,075	1.000	-	747	1.000	-
		NDMA-exposed	2,785	1.275 (1.207–1.346)	< 0.001*	1,106	1.315 (1.206–1.433)	< 0.001*	756	1.200 (1.082–1.332)	< 0.001*
	2-year exc. ^{d)}	NDMA-unexposed	2,057	1.000	-	815	1.000	-	562	1.000	-
		NDMA-exposed	2,059	1.118 (1.051–1.190)	< 0.001*	835	1.194 (1.083–1.317)	< 0.001*	565	1.100 (0.977–1.239)	0.114
1:1:1 PSM ^{c)}	Overall	NDMA-unexposed	7,153	1.000	-	2,726	1.000	-	2,417	1.000	-
		Eventually NDMA-unexposed	1,877	0.974 (0.921–1.030)	0.354	754	1.096 (1.002–1.199)	0.044	528	0.967 (0.870–1.075)	0.536
		NDMA-exposed	2,501	1.054 (1.001–1.110)	0.047	935	1.097 (1.008–1.193)	0.032	637	0.951 (0.861–1.051)	0.325

Supplementary Table 7. Continued

	6 mon exc. NDMA-unexposed	2,078	1.000	-	823	1.000	-	598	1.000	-
	Eventually NDMA-unexposed	1,669	1.466 (1.371–1.567)	< 0.001*	684	1.650 (1.484–1.834)	< 0.001*	485	1.526 (1.346–1.729)	< 0.001*
	NDMA-exposed	2,239	1.553 (1.459–1.654)	< 0.001*	871	1.649 (1.492–1.824)	< 0.001*	583	1.439 (1.275–1.623)	< 0.001*
	1-year exc. NDMA-unexposed	1,818	1.000	-	723	1.000	-	517	1.000	-
	Eventually NDMA-unexposed	1,412	1.282 (1.194–1.377)	< 0.001*	589	1.443 (1.290–1.614)	< 0.001*	417	1.355 (1.186–1.548)	< 0.001*
	NDMA-exposed	1,993	1.416 (1.326–1.512)	< 0.001*	760	1.450 (1.305–1.612)	< 0.001*	521	1.313 (1.157–1.490)	< 0.001*
2-year exc. ^{d)}	NDMA-unexposed	1,374	1.000	-	548	1.000	-	377	1.000	-
	Eventually NDMA-unexposed	987	1.052 (0.969–1.143)	0.229	417	1.183 (1.039–1.346)	0.011	298	1.170 (1.003–1.365)	0.045
	NDMA-exposed	1,422	1.178 (1.093–1.270)	< 0.001*	567	1.248 (1.107–1.406)	< 0.001*	382	1.151 (0.996–1.330)	0.057
PSM	Cancer	Uterine cancer ^{a)}								
		Event	aHR (95% CI)	<i>p</i> value						
Before PSM ^{b)} Overall	NDMA-unexposed	4,793	1.000	-						
	Eventually NDMA-unexposed	355	0.933 (0.835–1.042)	0.220						
	NDMA-exposed	648	1.004 (0.922–1.093)	0.933						
6 mon exc.	NDMA-unexposed	2,789	1.000	-						
	Eventually NDMA-unexposed	339	1.263 (1.125–1.419)	< 0.001*						
	NDMA-exposed	619	1.264 (1.155–1.383)	< 0.001*						
1-year exc.	NDMA-unexposed	2,527	1.000	-						
	Eventually NDMA-unexposed	301	1.198 (1.059–1.355)	0.004						
	NDMA-exposed	558	1.206 (1.109–1.326)	< 0.001*						
2-year exc.	NDMA-unexposed	2,053	1.000	-						
	Eventually NDMA-unexposed	235	1.175 (1.022–1.350)	0.023						
	NDMA-exposed	425	1.132 (1.017–1.261)	0.023						

Supplementary Table 7. Continued

1:1 PSM ^{c)}	Overall	NDMA-unexposed	358	1.000	-
		NDMA-exposed	202	0.983 (0.814–1.187)	0.859
	6 mon exc.	NDMA-unexposed	168	1.000	-
		NDMA-exposed	194	1.344 (1.086–1.663)	0.007
	1-year exc.	NDMA-unexposed	146	1.000	-
		NDMA-exposed	183	1.406 (1.125–1.757)	0.003*
	2-year exc.	NDMA-unexposed	119	1.000	-
		NDMA-exposed	139	1.244 (0.970–1.594)	0.085
	1:1:1 PSM ^{c)} Overall	NDMA-unexposed	351	1.000	-
		Eventually NDMA-unexposed	108	0.903 (0.714–1.142)	0.395
	6 mon exc.	NDMA-unexposed	110	1.000	-
		Eventually NDMA-unexposed	104	1.532 (1.162–2.020)	0.002*
		NDMA-exposed	132	0.882 (0.706–1.103)	0.272
		NDMA-exposed	126	1.418 (1.088–1.849)	0.010
	1-year exc.	NDMA-unexposed	92	1.000	-
		Eventually NDMA-unexposed	96	1.607 (1.199–2.154)	0.001
		NDMA-exposed	120	1.517 (1.148–2.006)	0.003*
		NDMA-unexposed	73	1.000	-
	2-year exc.	Eventually NDMA-unexposed	79	1.530 (1.109–2.112)	0.010
		NDMA-exposed	82	1.197 (0.870–1.648)	0.270

PSM, propensity score matching; NDMA, N-nitrosodimethylamine; aHR, adjusted hazard ratio; CI, confidence interval; mon, month; exc., excluded.

^{a)}All analyses for prostate, breast or uterine cancers were performed limited to men or women.

^{b)}All hazard ratios before PSM were adjusted for age, sex, Charlson comorbidity index, being a prevalent user, and the year of the first observed valsartan prescription.

^{c)}All hazard ratios after PSM were adjusted for age, sex, being a prevalent user, and the year of the first observed valsartan prescription.

^{d)}Each model has the lowest Akaike information criterion.

*Statistically significances at the threshold using Bonferroni correction for 13 tests ($p < 0.004$).